Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-01-26 00:00:00 ET · period of report 2026-01-22 · accession 0000875320-26-000014 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-01-26 | 2026-01-22 | VRTX | Biller Jonathan | EVP, CLO | A - Grant | $0.00 | +9,068 | 21.6K | +72% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-22 | A | A | 2,774 | $0.00 | 24,374 | D | — | — | (F2) Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. |
| 2 | Common | Common Stock | 2026-01-22 | A | A | 6,294 | $0.00 | 21,600 | D | — | — | (F1) Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. |